Menu

Vlad Denic on Exploring New Fields and Failing Successfully

The Harvard professor is pursuing fundamental questions about autophagy, protein homeostasis, and other cellular processes, and he’s always on the lookout for his next new topic.

Dec 1, 2016
Ben Andrew Henry

© PAUL SIMCOCKAs a graduate student studying cell biology at the University of California, San Francisco, Vlad Denic was not interested in projects suggested by his mentor that were sure to result in a publication. Instead, he devised his own experiments, screening for genes involved in sphingolipid metabolism, among other research pursuits. After seven years, Denic pulled together a manuscript on a lipid-synthesizing enzyme only to have it rejected by Cell for lacking general interest. He submitted a different manuscript, this one on an artificial lipid-synthesis technique, to Science a year later and was rejected again, this time on the grounds that his findings were not novel enough.

“I’m okay with failure,” Denic says now. “As long as it prompts me to come up with something new.” His persistence paid off during an experiment with the enzymes that help produce very long fatty acid chains, important cellular building blocks. Denic observed that by adjusting the position of one amino acid, he could control the size of the chain, a mechanism he called a “molecular caliper.”1 The finding earned him a publication in Cell and drew his eight years of grad school to a close.

During those years, Denic built a reputation for inventive experimentation that helped him immediately land a faculty position at Harvard University in 2008. Initially, his lab focused on tail-anchored (TA) proteins, a broad and vital class of membrane-bound molecules involved in diverse cellular processes, from vesicle fusion to cell death. Denic, with his first grad students and postdocs, described the cellular machinery that ferries some of these proteins from ribosomes to their destinations in the endoplasmic reticulum, a process needed for efficient organelle assembly.2

But after a string of papers that answered key questions about this complex system, Denic began to look around for fresh projects. “Once [Denic] feels he understands the basics of some problem, he has absolutely no fear of moving into other areas,” observes Manu Hegde, a long-time friend of Denic who studies TA proteins at the Medical Research Council Laboratory of Molecular Biology in the U.K. “He’s a very original thinker.”

As the TA protein studies wound down, Denic says, “we started shifting focus toward selective autophagy,” a process by which cells tag, capture, and recycle damaged or toxic material. “We thought there would be many big mountains left to climb.” His group discovered that yeast cells trigger autophagy on demand through the flip of a molecular switch, rather than at a constant rate, as had previously been thought.3 The mechanism’s existence suggested that autophagy could be ratcheted up or down to keep pace with a cell’s needs, Denic and his coauthors reasoned. Lately, the team has been using CRISPR-induced random mutations to screen for uncharacterized genes in mammalian cells that play critical roles in autophagy.

Denic has spent the last few months on sabbatical exploring yet another new topic in a familiar city, San Francisco. Before he returned to the Bay Area, his Harvard lab identified a transcription factor that prevents misfolded and toxic proteins from building up in the cell. Denic is now exchanging ideas and techniques related to protein homeostasis with scientists at Calico, a biotech venture started by Google to study aging. When he returns to Harvard in the spring, Denic says he plans to investigate how the protein folding process erodes over time, a line of inquiry that may shed some light on the cellular consequences of aging. 

References

  1. V. Denic and J.S. Weissman, “A molecular caliper mechanism for determining very long-chain fatty acid length,” Cell, 130:663-77, 2007. (Cited 156 times)
  2. F. Wang et al., “The Get1/2 transmembrane complex is an endoplasmic-reticulum membrane protein insertase,” Nature, 512:441-44, 2014. (Cited 13 times)
  3. R.A. Kamber et al., “Receptor-bound targets of selective autophagy use a scaffold protein to activate the atg1 kinase,” Mol Cell, 59:372-81, 2016. (Cited 14 times)

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!